Drug Database
IN

interferon (DS Sumiferon / Humoferon / Sumiferon)

✓ Approved

Pacific Pharmaceuticals · IFNAR2

什么是 interferon?

interferon 是一种治疗药物,由Pacific Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名DS Sumiferon, Humoferon, Sumiferon
公司Pacific Pharmaceuticals
分子靶点IFNAR2
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

作用机制

分子靶点

interferon 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

interferon 针对 9 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hairy cell leukaemia✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Respiratory papilloma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic myeloid leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedBMC medical research methodology2026-11-19

Not a panacea: the role of presenting descriptive statistics and effect sizes in abstracts on medical students' misconceptions about p-values.

Eisenhut Frieder S FS, Wiemann Leon L, Binder Karin K, Fischer Martin R MR et al.

Most scientific studies report inferential statistical results using p-values. For clinical decision-making, correctly interpreting the results of significance tests is particularly important, for example, to differentiate between statistical significance and clinical relevance. However, p-values are frequently misinterpreted, and reporting effect sizes alongside p-values has therefore been recommended to support the interpretation of statistical results. We examined 121 medical students' misconceptions about p-values when presented with three fictitious but realistic medical abstracts containing comparisons of group means and t-tests. Medical context, sample size, p-value, and effect size were systematically varied across the abstracts (abstract 1: N1 = N2 = 7,500; p < 0.001; Cohen's d = 0.12; abstract 2: N1 = N2 = 10; p = 0.04; Cohen's d = 1.00; abstract 3: N1 = N2 = 40; p = 0.09; Cohen's d = 0.38). We varied the amount of statistical information provided in each abstract (information set 1: sample size and p-value; information set 2: sample size, p-value, means, and standard deviations; information set 3: the same information and effect size Cohen's d). We examined whether additional statistical information was associated with fewer misconceptions and how the provided information influenced students' perceived effect size. In all versions, a high proportion of medical students across all semesters of study demonstrated multiple misconceptions about p-values. The number of endorsed misconceptions substantially decreased with the provision of more statistical information only in the context with a large sample size, a statistically significant result, and a very small effect size. In this context, providing additional statistical information reduced the tendency to infer clinical relevance and effect magnitude directly from statistical significance. Although reporting standardized effect sizes has repeatedly been recommended, their inclusion alone appears insufficient to prevent mis- and overinterpretations of inferential statistical results. The interpretation of statistical evidence should be addressed more intensively and longitudinally throughout medical education, including by explicitly addressing typical misconceptions. Alternative teaching approaches to statistical inference, including simulation-based approaches, should also be considered.

PMID 43052765
阅读全文 →
PubMedNature communications2026-11-19

Tumor-intrinsic PTPN12 suppresses anti-tumor immunity in colorectal cancer by restraining a dual epigenetic and cytoskeletal dsRNA sensing program.

Huo Yachang Y, Tian Yijun Y, Wang Dan D, Ping Yu Y et al.

Innate sensing of endogenous double-stranded RNA and the ensuing interferon response are crucial for the efficacy of immune checkpoint inhibition. Microsatellite stable colorectal cancer characteristically lacks this response, remaining immune-refractory with undefined intrinsic regulators. Here, through an in vivo clustered regularly interspaced short palindromic repeats screen, we identify PTPN12 as a physiological barrier that suppresses double-stranded RNA sensing and interferon response. TRIM28 was identified as a direct PTPN12 substrate here; PTPN12 removes phosphorylation at Y370 to stabilize repressive complexes and silence transposable elements, while concurrently rewiring the adhesive cytoskeleton to disrupt the spatially organization of cytosolic double-stranded RNA required for efficient innate sensing. Pharmacological inducible PTPN12 knockdown inhibits pre-established tumor growth and overcomes immunotherapy resistance in vivo, recapitulating PTPN12 ablation-induced massive double-stranded RNA accumulation. Our findings reveal a role for PTPN12 in coupling epigenetic silencing with cytoskeletal surveillance, suggesting potential strategies to augment anti-tumor immunity and overcome immunotherapy resistance in microsatellite stable colorectal cancer.

PMID 43052240
阅读全文 →
PubMedPulmonology2026-11-19

Nebulized interferon-β1a (SNG001) in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.

Qin Jinlv J, Wang Guizuo G, Han Dong D

This systematic review and meta-analysis aimed to determine the efficacy of nebulised interferon-β1a (SNG001) in patients with Coronavirus disease-2019 (COVID-19). A systematic search was conducted across PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Studies were searched up to November 2025. Randomised controlled trials (RCTs) on treatment of COVID-19 with SNG001, compared with placebo or standard of care, were reviewed. Data were analysed using the RevMan Version 5.1 (The Cochrane Collaboration). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Four RCTs (enrolling 1055 participants) met the inclusion criteria. The proportion of patients with hospitalisations (data extracted from two RCTs) (RR 0.16, 95% CI 0.03 to 0.88), and serious adverse events (RR 0.65, 95% CI 0.47 to 0.90) were significantly fewer in SNG001 groups. There was no statistically significant difference in all-cause mortality (RR 0.72, 95% CI 0.37 to 1.39), patients non-recovery at day 28 (RR 0.87, 95% CI 0.65 to 1.17), and adverse event (RR 0.97, 95% CI 0.90 to 1.04) between the two groups. Nebulised SNG001 was safe and associated with a reduction in COVID-19-related hospital admission. SNG001 shows a potential benefit for outpatients with COVID-19, but it requires larger clinical trials for future validations, particularly in vaccinated and previously infected populations.

PMID 43053745
阅读全文 →
PubMedAlzheimer's research & therapy2026-11-19

Resting-state EEG features of cognitive fluctuations across the Lewy body disease spectrum.

Negida Ahmed A, Lageman Sarah K SK, Ono Kenchiro K, Ahsan Md Moinul MM et al.

Cognitive fluctuations (CF) are a core feature of Lewy body dementia (LBD) that negatively impact quality of life. Despite their prevalence and negative impact, CF are challenging to identify clinically. The goal of this study was to identify easily obtainable EEG features associated with CF across the spectrum of Lewy body disease (LB). We conducted a cross-sectional study of 53 patients prospectively enrolled through the outpatient clinics of the Department of Neurology at Virginia Commonwealth University. Based on the Clinician Assessment of Fluctuations, participants were categorized as LB disease without CF (LB-CF) or LB disease with CF (LB + CF). All participants underwent a resting-state EEG recording with eyes closed for at least 3 min. EEG data were preprocessed and the following features were extracted: dominant frequency (DF), dominant frequency variability (DFV), dominant frequency prevalence (DFP), and individual alpha peak frequency (IAF). We applied Kruskal-Wallis tests and logistic regression models to evaluate differences in EEG features between study groups. We analyzed EEG features for 29 LB + CF and 24 LB-CF participants. Compared to the LB-CF group, the LB + CF group had significantly lower DF, DFP-alpha, and IAF in all derivations (all p < 0.05). In logistic regression analysis adjusting for age, sex, and MoCA score, these EEG features remained significant predictors of group (LB + CF vs. LB-CF, all q < 0.05). The elastic-net logistic regression model identified five predictors (anterior DFP-alpha, anterior DFP-pre-alpha, anterior DF, temporal DF, and temporal IAF) achieving an AUC of 0.86, whereas anterior DFP-alpha alone achieved an AUC of 0.85. Among patients with LB disease, resting-state EEG features were associated with CF and were significant predictors of CF even after adjustment for age, sex, and MoCA. The development of an EEG-based biomarker of CF using this set of features could improve diagnosis of Lewy body dementia.

PMID 43053228
阅读全文 →
PubMedInternational journal of urology : official journal of the Japanese Urological Association2026-11-19

Re: A Novel Alpha-Numeric Classification of Urethral Duplication and Triplication-Proposal for a "Blind-Ending" Suffix.

Cayirli Hasan H, Beci Faruk F

PMID 43053266
阅读全文 →
PubMedCellular and molecular life sciences : CMLS2026-11-19

Stimulation of plasmin activity by acetylsalicylic acid hinders prion propagation in vitro and in vivo.

Trinh Trang H T THT, Yoo Miryeong M, Byun Sanghoon S, Park HyunJung H et al.

Autocatalytic propagation of PrPSc, the misfolded isoform of the cellular prion protein (PrPC), is the hallmark of fatal, neurodegenerative disorders termed prion diseases. Physiologically, PrPC undergoes α-cleavage, generating C1 and N1 fragments, which disrupts the region necessary for conversion of PrPC to PrPSc. Recently, we reported that plasmin, an enzyme that cleaves PrPC at the α-site, substantially inhibits PrP conversion and prion propagation. Here, we investigated whether stimulation of plasmin activity by acetylsalicylic acid (ASA) would enhance α-cleavage of PrPC and suppression of prion propagation in vitro and in vivo. ASA stimulated plasmin to induce α-cleavage of recombinant PrP, preventing its aggregation, in PrP cleavage and PrP self-aggregation assays. ASA enhanced plasmin-mediated suppression of PrPSc propagation in protein misfolding cyclic amplification. Furthermore, ASA significantly enhanced endogenous plasmin activity, increased C1 fragment generation, and reduced the PrPSc level in both prion-infected cultured cells and mouse brains. These events were translated to the reduction of prion infectivity in standard scrapie cell assay. In addition, ASA prolonged incubation time, prevented disease-associated neuropathology, and attenuated the reduction of synaptic marker proteins in a mouse model of prion disease. Our findings demonstrate that ASA-mediated activation of plasmin promotes α-cleavage of PrPC, hindering prion replication and disease progression in vitro and in vivo. These results suggest that prion suppression is feasible by control of plasmin activity associated with cellular processing of PrPC and propose a potential therapeutic target for prion diseases.

PMID 43052568
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多interferon